Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 1526

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 16
Chunk 1526
---
5

F-4

CERO THERAPEUTICS HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED
STOCK AND 
STOCKHOLDERS’ DEFICIT

    Convertible
    Preferred Stock  

    Additional  
    Stock  
       
    Total 

    Series
    A  
    Series
    B  
    Series
    C  
    Series
    A Common Stock  
    Paid-in  
    Subscriptions  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Shares  
    Amount  
    Capital  
    Receivable  
    Deficit  
    Deficit 

    Balance
    at 2/14/2024 (Successor) 
     10,089  
    $8,937,852  
     -  
    $-  
     -  
    $     -  
     145,318  
    $15  
    $53,899,871  
    $(2,000,000) 
    $(63,185,641) 
    $(2,347,903)
  
    Issuance
of shares of Series A Preferred Stock upon exercise of Series A Preferred Warrants, net of issuance costs of $14,693 
     1,875  
     1,529,493  
     -  
     -  
     -  
     -  
     -  
     -  
     (1,507,600) 
     1,507,600  
     -  
     1,529,493 
  
    Issuance of Series B shares sold to investors for cash, net of issuance costs of $81,684 
     -  
     -  
     626  
     500,000  

     (81,684) 
     -  
        
     418,316 
  
    Issuance
    of Series A shares for rounding purchases 
     3  
     1,875  
     -  
     -  

     -  
     -  
     130  
     -